Jaclyn Phillips

White & Case (Washington)
Lawyer (Associate)

Jaclyn Phillips is an associate in the firm’s Global Antitrust/Competition practice group, who focuses on complex litigation in the areas of antitrust, intellectual property, and class actions. She has notable appellate experience, and counsels clients on antitrust issues. Jaclyn represents several leading global pharmaceutical companies, including Allergan and Boehringer Ingelheim, in class action litigation matters at the cutting edge of antitrust and intellectual property. Jaclyn also has an extensive pro bono practice, with a particular focus on immigration matters. She has represented clients who were granted asylum in the United States. Jaclyn graduated from Georgetown University Law Center cum laude in 2013, where she served as an Articles & Notes Editor on the American Criminal Law Review.

Linked authors

White & Case (Washington)
White & Case (Washington)
White & Case (Washington)
White & Case (New York)
White & Case (Washington)

Articles

109 Bulletin

Michael Mahaffey, Mark J. Gidley, Martin M. Toto, Kathryn Jordan Mims, Jaclyn Phillips, Trina Shek Rizzo The US DoJ issues a business review letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute equipment and medicine

41

On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute personal (...)

Mark J. Gidley, Martin M. Toto, Kathryn Jordan Mims, Jaclyn Phillips, Trina Shek Rizzo, Michael Mahaffey The US DoJ issues its first business review letter under the DoJ-FTC expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute protective equipment

34

On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute personal (...)

Jaclyn Phillips, Trina Shek Rizzo, Kathryn Jordan Mims, Mark J. Gidley The US Senate passes the CARES Act as a response to the COVID-19 crisis and tackles numerous issues on several fronts to stabilise the economy

34

The Coronavirus Aid, Relief, and Economic Security ("CARES") Act provides no modifications to, or relief from, the US antitrust laws (specifically, the Sherman Act, 15 U.S.C. §§ 1-38; Clayton Act, 15 U.S.C. § 12-27; and Robinson-Patman Act, 15 U.S.C. § 13). But some major businesses are forming (...)

Send a message